ARS Pharmaceuticals, Inc. — Director's Dealing 2024

Jun 24, 2024

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: ARS Pharmaceuticals, Inc. (SPRY)
CIK: 0001671858
Period of Report: 2024-06-20

Reporting Person: Kelly Michael (N/A)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2024-06-20	Stock Option (right to buy)	$7.73	A	40000	Acquired	2034-06-19	Common Stock (40000)	Direct

Footnotes

F1: The shares subject to the option will vest in full on the earlier of June 20, 2025 or the date of the Issuer's 2025 annual meeting of stockholders, which date has not been set by the Issuer's Board of Directors.